Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 9/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 4/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8108532 | 0.80 | CNR2 (0.38) | HPGDSCNR2CNR1SPHK1BACE1 | |
| SCHEMBL8124149 | 0.80 | HPGDS (0.40) | HPGDSCNR2CNR1SCN2ASPHK1 | |
| SCHEMBL8119014 | 0.76 | KCNH2 (0.51) | HPGDSCNR2CNR1SPHK1BACE1 | |
| SCHEMBL8108537 | 0.74 | SPHK1 (0.42) | HPGDSCNR2CNR1SCN2ASPHK1 | |
| SCHEMBL7140243 | 0.73 | SCN2A (0.42) | HPGDSCNR2CNR1SCN2ASPHK1 | |
| SCHEMBL7140240 | 0.73 | SCN2A (0.42) | HPGDSCNR2CNR1SCN2ASPHK1 | |
| SCHEMBL7143478 | 0.73 | KCNH2 (0.49) | HPGDSCNR2CNR1SCN2ABACE1 | |
| SCHEMBL7138368 | 0.72 | CNR2 (0.47) | HPGDSCNR2CNR1SCN2ABACE1 | |
| SCHEMBL8150273 | 0.72 | HPGDS (0.51) | HPGDSCNR2CNR1SCN2ABACE1 | |
| SCHEMBL8190593 | 0.72 | KCNH2 (0.48) | HPGDSCNR2CNR1SCN2ABACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0996443-A1 | CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2000-05-03 | — | — | EP | claimed |
| WO-1999001128-A1 | CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1999-01-14 | — | — | WO | claimed |
| US-6121260-A | Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives | NEUROGEN CORPORATION (US) | 2000-09-19 | — | — | US | disclosed |